EP3844737B1 - Non-biological skin model - Google Patents

Non-biological skin model Download PDF

Info

Publication number
EP3844737B1
EP3844737B1 EP19758994.8A EP19758994A EP3844737B1 EP 3844737 B1 EP3844737 B1 EP 3844737B1 EP 19758994 A EP19758994 A EP 19758994A EP 3844737 B1 EP3844737 B1 EP 3844737B1
Authority
EP
European Patent Office
Prior art keywords
skin
advantageously
lipid composition
polymeric material
biological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19758994.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3844737A1 (en
Inventor
Florine EUDIER
Michel GRISEL
Céline PICARD
Géraldine SAVARY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Le Havre Normandie
Original Assignee
Universite Le Havre Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Le Havre Normandie filed Critical Universite Le Havre Normandie
Publication of EP3844737A1 publication Critical patent/EP3844737A1/en
Application granted granted Critical
Publication of EP3844737B1 publication Critical patent/EP3844737B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D191/00—Coating compositions based on oils, fats or waxes; Coating compositions based on derivatives thereof
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30—Anatomical models

Definitions

  • the invention relates to a non-biological skin model that mimics skin surface properties and its method of preparation.
  • the invention relates to a non-biological skin model comprising a polymeric material reproducing skin surface topography that is coated with a lipid composition in order to reproduce skin surface free energy.
  • Skin is the most extensive and heaviest human organ. It plays a fundamental protective role for our whole body. One of its most important functions is to control the penetration of external compounds and microorganisms into human body and to limit excessive water loss.
  • This skin barrier property is mainly related to the stratum corneum, its external layer composed of dead cells, the corneocytes, kept stuck together thanks to intercellular lipids which act as stratum corneum "cement". This external dead layer is in direct contact with external environment and with any product applied onto skin surface. Both corneocytes and intercellular lipids integrity condition the efficacy of skin barrier function and the interaction between the skin and its environment.
  • Non-biological skin models are hence commercially available such as the Vitroskin ® which has been specifically developed to mimic skin surface properties (pH, ionic strength, physico-chemistry). The main disadvantage of those commercial products is that their composition remains unknown and unchangeable, thus they can be considered as "black boxes”.
  • NBSM non-biological skin model
  • the present invention meets the aforementioned need.
  • a non-biological skin model comprising a polymeric material reproducing skin surface topography that is coated with a specific and controlled lipid composition with a surface concentration of the lipid composition on the polymeric material between 500 ⁇ g/cm 2 and 2500 ⁇ g/cm 2 , is suitable for mimicking skin surface properties, chemical composition and topography thus imitating its physico-chemistry.
  • the Non-Biological Skin Model (NBSM) according to the invention has the advantage to reproduce real human surface topography.
  • the present NBSM technology is further fully versatile, it represents high potential as a way to deepen the understanding of the skin micro relief impact on its physico-chemistry and on cosmetic products interactions and spreading behaviour onto the skin.
  • An object of the invention is thus a non-biological skin model (NBSM) comprising a polymeric material reproducing skin surface topography that is coated with a lipid composition, wherein the polymeric material is a material having a surface free energy ( ⁇ ) of between 14 and 60 mJ/m 2 ; wherein the lipid composition comprises from 14 % to 60 % of triglycerides, from 2 % to 40 % of free fatty acids, from 4 % to 30 % of wax esters, from 3 % to 20 % of squalene, and from 1 % to 10 % of cholesterol; and wherein the surface concentration of the lipid composition on the polymeric material is between 500 ⁇ g/cm 2 and 2500 ⁇ g/cm 2 .
  • NBSM non-biological skin model
  • a second object of the invention is a method for preparing a non-biological skin model, comprising the following steps:
  • a third object of the invention is the use of the non-biological skin model of the invention for evaluating cosmetic products performance or evaluating the effect of pollution on skin surface properties.
  • a fourth object of the invention is the use non-biological skin model of the invention for evaluating the physico-chemistry of the skin, or evaluating the impact of the lipid composition or the skin topography on the surface free energy ( ⁇ ) of the skin.
  • non-biological skin model refers to non-biological experimental systems that recreate aspects of human skin surface topography, chemistry, physico-chemistry, representing healthy or damaged skin.
  • skin surface topography refers to the depth, density, and arrangements of the lines and/or grooves of the skin.
  • polymeric material refers to a material reproducing skin surface topography and to which a coating layer may be stably affixed and removable.
  • polymeric material refers to a material reproducing skin surface topography and to which a coating layer may be stably affixed and removable.
  • polymeric support refers to a material reproducing skin surface topography and to which a coating layer may be stably affixed and removable.
  • substrate refers to a material reproducing skin surface topography and to which a coating layer may be stably affixed and removable.
  • lipid composition refers to a composition that mimics skin surface lipid composition. Said composition is chemically close to the composition of skin sebum and epidermal lipids, i.e. the lipid composition comprises the appropriate types of lipids at levels that match human values.
  • the terms “lipid composition”, “artificial skin lipids”, “coating layer”, “lipid coating”, “skin lipids layer”, are used as synonyms. In all the embodiments of the invention, all percentages of materials in the lipid composition are expressed by weight in relation to the total weight of the lipid composition, unless specifically stated otherwise.
  • skin print with a negative relief of the skin refers to a mold created by placing a suitable material on the keratinous tissue or body part of interest, and removing the material from the tissue.
  • the resulting skin print with negative relief also called “negative mold” contains an impression of the keratinous tissue or body part and thus can be used to create a positive mold.
  • surface free energy refers to a physico-chemical property of materials. It corresponds to the energy needed to increase the size of a single phase surface by a unit of area. From a microscopic scale, it characterizes the forces involved in the material integrity such as Van der Waals forces or the hydrogen bounding. From a macroscopic scale, surface free energy is involved in surface wettability.
  • the surface free energy can be measured by several methods known by the one skilled in the art, for example by contact angle calculation, using the sessile drop method. The method used in the present invention is particularly disclosed in example 2.C.
  • surface concentration refers to the amount of lipids coated onto the polymeric material surface by unit area.
  • the surface concentration can be measured by several methods known by the one skilled in the art, for example by weighing the polymeric material before and after lipid coating or using a sebumeter ® .
  • skewness factor refers to the parameter that describes surface morphology: a positive Ssk value corresponds to a surface showing peaks and protuberance projecting above the average height whereas a negative Ssk value corresponds to a tray surface with deep scratches and pores.
  • the skewness factor can be measured by several methods known by the one skilled in the art, for example from 3D images of surfaces according to the ISO 25178 norm, using the mountains Map ® software (Digital Surf SARL, Besan affair, France).
  • contact angle refers to the angle ⁇ formed by a liquid droplet once deposited onto a solid surface ( Figure 1 ).
  • the contact angle can be measured for example by using a goniometer and the sessile drop method.
  • viscoelastic material refers to a material whose mechanical properties when subjected to deformation have on the one hand an elastic component and on the other hand a viscous component.
  • a purely elastic material deforms under stress and then goes back to its original form when the stress is stopped.
  • a purely viscous material deforms linearly with respect to the stress and does not return to its original form when the stress is stopped.
  • a viscoelastic material therefore has an intermediate behavior between these two mechanical characteristics.
  • Lipids that are not crystallized means that the geometric shape crystals of the lipid coating have dimensions lower than 10 ⁇ m, preferably lower than 5 ⁇ m, as measured on polarized light microscopy images.
  • the first object of the invention is a non-biological skin model (NBSM) comprising a polymeric material reproducing skin surface topography that is coated with a lipid composition, wherein the polymeric material is a material having a surface free energy ( ⁇ ) of between 14 and 60 mJ/m 2 ; wherein the lipid composition comprises from 14 % to 60 % of triglycerides, from 2 % to 40 % of free fatty acids, from 4 % to 30 % of wax esters, from 3 % to 20 % of squalene, and from 1 % to 10 % of cholesterol, and wherein the surface concentration of the lipid composition on the polymeric material is between 500 ⁇ g/cm 2 and 2500 ⁇ g/cm 2 .
  • NBSM non-biological skin model
  • the non-biological skin model (NBSM) thus comprises two distinct parts combined together (see Figure 2 ): the first part is a polymeric material which reproduces skin surface topography, and the second part is an artificial skin lipids mixture which mimics lipid composition of skin.
  • the first part is a polymeric material which reproduces skin surface topography
  • the second part is an artificial skin lipids mixture which mimics lipid composition of skin.
  • at least one surface of the polymeric material is coated with the lipids composition.
  • the polymeric material thus advantageously acts as a substrate.
  • the polymeric material may be in any shape or form suitable for application of a product and for analysis of the substrate and/or its lipid coating.
  • the polymeric material may be in the form of a sheet having two substantially planar, parallel surfaces, and a substantially uniform thickness.
  • the thickness of the polymeric material is from about 1 mm to about 1 cm.
  • the polymeric material can be in the form of a body part, for example an arm, leg, hand, foot, finger, toe, upper torso, lower torso, etc.
  • the polymeric material is a material having a surface free energy ( ⁇ ) of between 14 and 60 mJ/m 2 .
  • ⁇ surface free energy
  • the polymeric material used in the invention is in particular a viscoelastic polymeric material.
  • the polymeric material used in the invention is selected from the group of materials comprising or consisting in polyurethane, polymethylmethacrylate, polypropylene, polyamide, polysaccharides, protein, silicone or mixture thereof.
  • the polymeric material used in the invention is selected from the group of materials comprising or consisting in polyurethane, polymethylmethacrylate, silicone, or mixture thereof.
  • the polymeric material is a silicone material having a surface free energy ( ⁇ ) of between 14 and 60 mJ/m 2 .
  • the polymeric material used in the invention may be a commercial silicone rubber such as the silicone DragonSkin ® 20.
  • the polymeric material can be formed by means known by the one skilled in the art, for example, using a skin print with a negative relief of the skin into which the material is poured and harden.
  • the skin print is advantageously a biocompatible silicon skin print such as the biocompatible silicon Body Double ® or Silflo ® , an alginate skin print, or a plaster skin print. More advantageously, the skin print is a biocompatible silicon skin print such as the biocompatible silicon Body Double ® or Silflo ® .
  • the lipid composition imitates skin surface lipid composition.
  • the lipid composition comprises from 14 % to 60 % of triglycerides, from 2 % to 40 % of free fatty acids, from 4 % to 30 % of wax esters, from 3 % to 20 % of squalene, and from 1 % to 10 % of cholesterol.
  • the lipid composition comprises triglycerides in a content from 14 % to 60 %, more advantageously from 25 % to 40 %, more advantageously from 28 % to 35 %, in particular 32 %, by weight.
  • the lipid composition comprises free fatty acids in a content from 2 % to 40 %, more advantageously from 20 % to 35 %, more advantageously from 25 % to 30 %, in particular 28 %, by weight.
  • the lipid composition comprises wax esters in a content from 4 % to 30 %, more advantageously from 15 % to 26 %, more advantageously from 20 % to 26 %, in particular 25 %, by weight.
  • the lipid composition comprises squalene in a content from 3 % to 20 %, more advantageously from 5 % to 15 %, more advantageously from 8 % to 20%, in particular 10 %, by weight.
  • the lipid composition comprises cholesterol in a content from 1 % to 10 %, more advantageously from 1 % to 6 %, more advantageously from 2 % to 6 %, in particular 4 %, by weight.
  • the lipid composition also comprises cholesteryl oleate in a content from 0 % to 9.5 %, more advantageously from 1 % to 9.5 %, more advantageously from 1 to 5 %, more advantageously from 1 to 3 %, particularly 2 %, by weight.
  • the lipid composition also comprises cholesterol sulphate in a content from 0% to 2%, more advantageously from 0 % to 1.8 %, in particular from 0 to 1.5 %.
  • the lipid composition also comprises linear alkanes in a content from 0% to 9%, more advantageously from 0 % to 7 %, in particular from 0 to 6 %.
  • the lipid composition also comprises sphingolipids in a content from 0% to 20%, more advantageously from 0 % to 19 %, in particular from 0 to 18 %.
  • the lipid composition advantageously comprises vitamin E in order to ensure the stability of the composition, advantageously in a content from 0 % to 1 % by weight, more advantageously in a content from 0.01 % to 1 % by weight, related to the total weight of the lipid composition.
  • the lipid composition of the invention thus comprises lipids at biologically relevant proportions, i.e. matched median values for humans and contained both saturated and monounsaturated wax ester, triglyceride, and free fatty acid components, and included cholesterol and advantageously cholesterol ester components and vitamin E.
  • lipid composition can be adapted to different type of skin (normal skin, dry skin, oily skin, combination skin%) or body area by adapting the contents of lipids.
  • the lipid composition can also be tuned to mimic cutaneous disorders link to a modification in skin lipids such as atopic dermatitis or symptoms of dry skin.
  • the lipid composition comprises from 25 % to 40 % of triglycerides, from 20 % to 35 % of free fatty acids, from 15 % to 26 % of wax esters, from 5 % to 15 % of squalene, from 1 % to 6 % of cholesterol, from 1 % to 5 % of cholesteryl oleate, from 0.01 to 1 % of vitamin E, from 0% to 1.8% of cholesterol sulphate, from 0% to 7% of linear alkanes, and from 0% to 19% of sphingolipids, by weight related to the total weight of the lipid composition.
  • the lipid composition comprises from 28 % to 35 % of triglycerides, from 25 % to 30 % of free fatty acids, from 20 % to 26 % of wax esters, from 8 % to 12 % of squalene, from 2 % to 6 % of cholesterol, and from 1 % to 3 % of cholesteryl oleate, from 0.01 to 1 % of vitamin E, , from 0% to 1.5% of cholesterol sulphate, from 0% to 6% of linear alkanes, and from 0% to 18% of sphingolipids, by weight related to the total weight of the lipid composition.
  • the lipid composition comprises 32 % of triglycerides, 28 % of free fatty acids, 25 % of wax esters, 10 % of squalene, 4 % of cholesterol, and 2 % of cholesteryl oleate, 0.01 of vitamin E, 0% of cholesterol sulphate, 0% of linear alkanes, and 0% of sphingolipids, by weight related to the total weight of the lipid composition.
  • the surface concentration of the lipid composition on the polymeric material is between 800 ⁇ g/cm 2 and 1800 ⁇ g/cm 2 . If the surface concentration of the lipid composition onto the polymeric material is greater than 2500 ⁇ g/cm 2 or lower than 500 ⁇ g/cm 2 , the non-biological skin model would have a surface free energy that is not in good agreement with the surface free energy calculated on human living skin explants, which is around 28.4 ⁇ 2.8 mJ/m 2 .
  • the non-biological skin model of the invention has a surface free energy ( ⁇ ) of between 24 mJ/m 2 and 45 mJ/m 2 , more advantageously of between 26 mJ/m 2 and 33 mJ/m 2 .
  • the lipid composition that coats the polymeric material is composed of lipids that are not crystallized.
  • “Not crystallized” means that the geometric shape crystals of the lipid coating have dimensions lower than 10 ⁇ m, preferably lower than 5 ⁇ m, as measured on polarized light microscopy images. Therefore, the non-biological skin model of the invention exhibits an apparent homogeneous lipid coating over its entire surface (cf. Figure 4C ).
  • the surface concentration of the lipid composition and the non-crystallized lipid coating may be obtained in particular thanks to the specific coating method of the lipid composition on the polymeric material. This specific method is described below.
  • the surface concentration of the lipid composition on the polymeric material and the homogenous lipid coating allows obtaining non-biological skin model that mimics the skin relief with much accuracy than the existed non-biological skin model.
  • the surface relief of the NBSM may be determined by analysing its roughness profiles and in particular the skewness factor.
  • the roughness parameters are listed in table 1 and may be measured from 3D images of surfaces according to the ISO 25178 norm, using the Mountains Map ® software (Digital Surf SARL, Besançon, France). The calculations have been performed on 3D images obtained using a Keyence Microscope VHX-1000 (Keyence Corporation TSE, Osaka, Japan) with the VH-Z100R lens at a magnification of x300. 3D images were recorded in transmission mode and assembled to obtain a 1600 x 1200 pixels size. Table 1.
  • Roughness parameters definitions Roughness parameter Unity Definition Sq ⁇ m Mean square height Ssk / Skewness factor Sp ⁇ m Maximum peaks height Sv ⁇ m Maximum valleys height Sz ⁇ m Maximum height Sa ⁇ m Arithmetic mean height
  • the non-biological skin model of the invention has a skewness factor between 0.0 and -2.5, more advantageously between -0.2 and -1.70, even more advantageously between -0.5 and -0.9.
  • the non-biological skin model of the invention has an arithmetic mean height (Sa) of between 10 ⁇ m and 80 ⁇ m, more advantageously between 15 ⁇ m and 50 ⁇ m, more advantageously between 17 and 25 ⁇ m.
  • Sa arithmetic mean height
  • the non-biological skin model of the invention has a maximum height (Sz) of between 75 ⁇ m and 2000 ⁇ m, more advantageously between 100 ⁇ m and 300 ⁇ m, more advantageously between 120 and 175 ⁇ m. These values are also in good agreement with in vivo literature data [5,9].
  • the non-biological skin model of the invention has a surface pH of between 4.0 and 7.0; more advantageously between 4.2 and 6.8; more advantageously between 4.8 and 5.9. These values are in good agreement with in vivo literature data that are between 4.2 and 6.8 [10]. This pH value has been measured using a Skin-pH-Meter ® (Courage + Khazaka Electronic GmbH, Koln, Germany) at ambient temperature (i.e. between 18°C and 25 °C) and 50% humidity.
  • a second object of the invention is a method for preparing a non-biological skin model, comprising the following steps:
  • the skin print with a negative relief of the skin, the polymeric material, and the lipid composition are as defined above in the description.
  • Steps a) and b) of the method of the invention are steps that can easily be made by methods known from the one skilled in the art, for example, using a skin print with a negative relief of the skin into which the material is poured and harden.
  • the skin print is advantageously a biocompatible silicon skin print such as the biocompatible silicon Body Double ® .
  • Step c) is also a step that can easily be made by method known from the one skilled in the art.
  • the one skilled in the art would know how to adapt the time and conditions of hardening to obtain a polymeric material having the expected physical and mechanical properties.
  • the hardening when using the silicone DragonSkin ® 20 as polymeric material, the hardening last at least 4h in ambient temperature (i.e. between 18 °C and 25 °C).
  • the particularity of the method of the invention lies in steps d) to g) and optionally d) to h).
  • the particularity of the method of the invention is that during the coating, the lipid composition that is applied onto the polymeric material is free of solvent.
  • the lipid composition comprises lipids dissolved in a solvent, said solvent being evaporated after the coating.
  • the step d) of preparing the lipid composition advantageously comprises a step d1) of dissolving the lipids in a solvent, and a step d2) of evaporating all the solvent.
  • step d1) the lipids are dissolved in a solvent to reach a concentration of between 1 and 20 g/L, more advantageously between 5 and 15 g/L of lipids.
  • the solvent is selected from the group consisting of dichloromethane, methanol, ethanol, chloroform, ethyl acetate, toluene, acetone, dimethylsulfoxide, and mixtures thereof.
  • the solvent is a mixture of chloroform and methanol, in particular in a ratio 2:1.
  • step e) is of at least 25 °C, advantageously between 65 °C and 200 °C, more advantageously between 65 °C and 100 °C.
  • the heating temperature should be sufficiently high to obtain a liquid composition but not too high to avoid the degradation of the lipids.
  • the polymeric material is brought to the same temperature than the lipid composition in step e).
  • Such a step allows avoiding temperature difference during the coating and thus allowing obtaining a more homogenous coating.
  • the method of the invention then comprises a step of applying the liquid lipid composition onto the polymeric material.
  • this step may be carried out by brush coating, spin coating or dip coating, advantageously by brush coating or spin coating.
  • step g) the obtained coated polymer material is optionally heated for homogenization (step g)), advantageously at temperature of at least 25 °C, advantageously between 65 °C and 200 °C, more advantageously between 65 °C and 100 °C.
  • step g) is carried out at the same temperature than the one used in step e).
  • all the steps of heating can be made by means known from the one skilled in the art, for example by placing the material into an oven.
  • Other heating means can be used such as hot plates, water bath or Peltier element.
  • the method of the invention allows obtaining a surface concentration of the lipid composition on the polymeric material that is between 500 ⁇ g/cm 2 and 2500 ⁇ g/cm 2 , more advantageously between 800 ⁇ g/cm 2 and 1800 ⁇ g/cm 2 .
  • the method of the invention optionally comprises a step h) of wiping off the excess lipid composition.
  • the step of wiping off the excess lipid composition is carried out by absorption.
  • the obtained coated polymer material is optionally heated for homogenization, advantageously at temperature of at least 25 °C, advantageously between 65 °C and 200 °C, more advantageously between 65 °C and 100 °C, more advantageously at the same temperature than the one used in steps e) and g).
  • the non-biological skin model thus obtained is then allowed to cool down to ambient temperature (i.e. between 18 and 25 °C).
  • the method of the invention allows thus the control of the surface concentration of the lipid composition on the polymeric material and therefore the control of the surface properties of the non-biological skin model obtained.
  • the non-biological skin model obtainable by the method of the invention has a surface free energy ( ⁇ ) of between 24 mJ/m 2 and 45 mJ/m 2 , more advantageously of between 26 mJ/m 2 and 33 mJ/m 2 .
  • the method of the invention allows obtaining a lipid coating which is composed of lipids that are not crystallized. Therefore, the method of the invention allows to obtain a non-biological skin model of the invention that exhibits an apparent homogeneous lipid coating over its entire surface (cf. Figure 4C ).
  • the non-biological skin model of the invention has a skewness factor between 0.0 and -2.5, more advantageously between -0.2 and -1.70, even more advantageously between -0.5 and -0.9.
  • the non-biological skin model of the invention has an arithmetic mean height (Sa) of between 10 ⁇ m and 80 ⁇ m, more advantageously between 15 ⁇ m and 50 ⁇ m, more advantageously between 17 and 25 ⁇ m.
  • Sa arithmetic mean height
  • the non-biological skin model of the invention has a maximum height (Sz) of between 75 ⁇ m and 2000 ⁇ m, more advantageously between 100 ⁇ m and 300 ⁇ m, more advantageously between 120 and 175 ⁇ m. These values are also in good agreement with in vivo literature data [5,9].Further, the non-biological skin model of the invention has a surface pH of between 4.0 and 7.0; more advantageously between 4.2 and 6.8; more advantageously between 4.8 and 5.9. These values are in good agreement with in vivo literature data that are between 4.2 and 6.8 [10].
  • Another object of the invention is thus a non-biological skin model obtainable by the method of the invention and advantageously having the above recited properties/characteristics.
  • the terms "the non-biological skin model (NBSM) of the invention” encompasses the NBSM of the invention as described above and the NBSM obtainable by the method of the invention as described above.
  • NBSM of the invention presents potential uses for the characterization of residual film present on skin after topical application.
  • Physicochemical study highlights the similarity between in vivo skin and NBSM behaviour in contact with cosmetic ingredients and emulsions. This can be of great interest to develop the knowledge of residual cosmetic film after application of raw materials or products such as gels or emulsions. This is a key area for sensory characterization but also for efficacy assessments.
  • the NBSM of the invention is also of great interest to study efficacy of new cosmetic products on skin surface but also for more fundamental researches.
  • Lipid composition can be tuned to mimic cutaneous disorders link to a modification in skin lipids such as atopic dermatitis or symptoms of dry skin. This can obviously constitute a novel way for characterizing those skin disorders and their physico-chemical consequences.
  • the NBSM of the invention may also be used to study the impacts of many external factors such as UV radiation, ozone or urban pollutants on skin surface physico-chemistry and to understand particles or microorganisms adhesion.
  • the NBSM can be stored during several days or weeks under obscurity without any modifications. If necessary, it just has to be placed into the oven at a sufficient temperature to liquefy the lipid mixture in order to re-homogenize the lipid coating.
  • the possibility of reusing the NBSM according to the invention is a great advantage over existing NBSM that cannot be retained after initial use. For example, the commercial non-biological skin model: Vitroskin ® (IMS, Inc., Milford, CT) cannot be retained once hydrated.
  • a third object of the invention is the use of the non-biological skin model of the invention for evaluating cosmetic products performance. Such a use may allow understanding the interaction (adverse or beneficial) of chemicals from consumer products, industrial chemicals and pharmaceuticals in direct and prolonged contact with the human skin.
  • Another object of the invention is the use non-biological skin model of the invention for evaluating the effect of pollution on skin surface properties.
  • Another object of the invention is the use non-biological skin model of the invention for evaluating the physico-chemistry of the skin, or evaluating the impact of the lipid composition or the skin topography on the surface free energy ( ⁇ ) of the skin.
  • Example 1 Preparation of a non-biological skin model according to the invention
  • NBSM non-biological skin model
  • a skin print was prepared in vivo using the biocompatible silicon Body Double ® (Creation Silicone, Jouy-en-Josas, France) to obtain a silicon surface with a negative relief of the skin.
  • This skin print was molded back using the silicone DragonSkin ® (DragonSkin 20, Creation-Silicone, Jouy-en-Josas, France) (see Fig. 3 ): after mixing together an equal amount of the two components of the kit, the Dragonskin ® was let degassing under high vacuum during 10 min. The viscous mixture was then poured onto the Body Double ® skin print and let harden for at least 4h.
  • the artificial sebum was then coated onto the previously described polymeric material.
  • Two coating protocols have been tested: one according to the invention and one comparative protocol.
  • the first protocol (referred as "Protocol 1") used a sebum solution in CHCl3/MeOH 3:7 at a concentration of 20g/L. Sebum solution was pulverized through a spraying pump on the polymeric material [5,12]. 10 pulverizations at a distance of 5 cm were performed on a 1 cm x 7 cm surface at ambient temperature. Surfaces as prepared were placed in a closed plastic tube to allow slow solvents evaporation and good homogeneity of the lipids coating.
  • the mean surface concentration obtained is 460 ⁇ g/cm 2 , as measured using the mass difference before and after lipid coating.
  • Protocol 2 (Invention)
  • the second protocol (referred as "Protocol 2" or protocol according to the invention) used pure sebum, without any solvent.
  • the solvents were evaporated from the artificial sebum solution.
  • Resulting lipids mixture was placed in an oven at 70°C until complete liquefaction.
  • the polymeric material was also placed in the oven at 70°C during 15 min to avoid temperature difference during deposit.
  • a thin pencil was used to apply a liquid lipid film onto the silicone support.
  • Coated support was then placed back in the oven during 5 min for homogenization at 70°C. Excess lipids were wiped off using absorbent paper, and the coated silicone was placed again in the oven during 5 min at 70°C.
  • the artificial skin model prepared as described was allowed to cool down to room temperature during few minutes.
  • the mean surface concentration obtained is 1500 ⁇ g/cm 2 , as measured using the mass difference before and after lipid coating.
  • BIO-EC Human living skin explants were furnished by BIO-EC (Longjumeau, France); they were obtained from plastic surgery of the abdominal area of a 29 years old Caucasian woman, with her consent.
  • the explants as prepared were placed in survival conditions using BIO-EC's explant medium (BEM) and maintained in an incubator at 37° C in 5% CO2. Half of the BEM was replaced by fresh one every two days. Eight explants were used for the determination of surface free energy. They were kept into the incubator until contact angle measurements. There were gently wiped before measurements, to eliminate residual BEM present on the surface.
  • BIO-EC BIO-EC's explant medium
  • the commercial Vitroskin ® (IMS, Inc., Milford, CT) has been characterized and used in the study. It is a reference in terms of non-biological skin models for physico-chemical studies.
  • the Vitroskin ® (VS) is a synthetic skin model made with proteins and lipids which mimics skin surface properties such as ionic strength, pH, topography and critical surface tension.
  • This NB skin model is used as skin substituent for in vitro SPF (Sun Protection Factor) measurements or for the study of emollients spreading.
  • SPF Un Protection Factor
  • Prior to use it required to be hydrated according to a standardized protocol developed by IMS.
  • the pieces of VS were placed during 16-24h at room temperature in a standard closed hydration chamber which contains 350g of a mixture water/glycerin 85:15, poured in the bottom [13].
  • Optical microscopy is used for comparing the surface of NBSM protocol 1 and NBSM protocol 2. Sebum thin layers of the two models were visualized using optical microscope in transmission mode (see Fig 4).
  • Figure 4 shows the microscopic images of the silicone support ( Fig. 4A ), the sebum thin layer deposed using protocol 1 ( Fig. 4B ) and protocol 2 ( Fig. 4C ) (Magnification x50, transmission, non-polarized light NPL and polarized light PL).
  • lipids on the polymeric support gives a granular aspect to the relief ( Fig. 4B et 4C ).
  • protocol 1 lipids clearly crystallize, as evidenced on Fig 4B : diamond-shape crystals are visible under polarized light. This crystallization, probably due to solvents evaporation, gives a glitter aspect to the surface, which is not appropriate for the lipid coating aspect. This crystallization is not observed for protocol 2 which exhibits an apparent homogeneous sebum layer over the entire surface ( Fig 4C ).
  • a FT-IR Spectrometer spectrum (PerkinElmer, Inc., Waltham, Massachusetts, USA), connected to the Spectrum software was used. 4 spectra were recorded for each measurement, using the ATR mode (ZnSe crystal). The range of vibrations was from 4 000 to 650 cm-1.
  • the lipids coated over the polymeric material of the NBSM protocol 2 were characterized by infrared spectroscopy and compared to the silicone support and the artificial sebum (see Fig 5 ).Vibrations associated to the artificial sebum are visible on the NBSM infrared spectrum. There are indicated by the black arrows on Figure 5 , and its associated wavenumbers are reported in table 3 and compared to in vivo data. Table 3: Wavenumbers (cm-1) for in vivo skin, the artificial sebum and the NBSM. Peak number (see Fig.
  • Wavenumbers associated to CH 2 symmetric stretch give information about lipids chain conformational packing. According to Mendelsohn and al [14], lipids chain packing evolves into the stratum corneum depth. Through the extreme surface (from 0 to 4 ⁇ m), CH 2 symmetric stretch wavenumber evolves from 2853 to 2849 cm -1 which corresponds to disordered and hexagonal chain packing. This is due to the specific lipids composition enriched in unsaturated lipids that covers the skin. Deeper into the stratum corneum, saturated lipids are predominant and show a highly ordered orthorhombic packing with associated wavenumbers between 2849 and 2847 cm -1 . This highly ordered packing provides to the stratum corneum its water barrier function.
  • NBSM protocol 2 is enriched in sebaceous lipids whereas they are absent on the VS.
  • VS shows vibrations associated to ceramides (1631 cm-1 and 1553 cm-1). Those lipids are involved in stratum corneum lipids organization and consequently in skin barrier function.
  • a Keyence Microscope VHX-1000 (Keyence Corporation TSE, Osaka, Japan) using the VH-Z100R lens at a magnification of x300 was used. 3D images were recorded in transmission mode and assembled to obtain a 1600 x 1200 pixels size.
  • 3D microscopy gives access to surface topography of the NBSM protocol 2 and the VS models and helps to study their roughness. 3D pictures obtained are presented on Figure 7 (7A for the NBSM protocol 2 and 7B for the VS models) and roughness profiles are summarized in Figure 8 (8A for the NBSM protocol 2 and 8B for the VS models).
  • the NBSM protocol 2 mimics forearm skin relief with much more accuracy than VS. As a consequence, in the aim to compare contact angle measurements performed on in vivo volar forearm the NBSM protocol 2 appears more suitable because surface roughness has a significant impact on contact angle measurements.
  • This last component includes the hydrogen bounding and the ⁇ -electron interactions.
  • ⁇ L is the liquid surface tension
  • ⁇ S is the solid surface free energy
  • ⁇ e the film pressure of the liquid
  • ⁇ SL the interfacial surface free energy
  • ⁇ SL ⁇ S LW + ⁇ L LW ⁇ ⁇ S LW ⁇ L LW 2 + 2 ⁇ S + ⁇ S ⁇ + ⁇ L + ⁇ L ⁇ ⁇ ⁇ S + ⁇ L ⁇ ⁇ ⁇ S ⁇ ⁇ L +
  • the surface free energy of the solid surface can be determined with using at least three reference liquids of known components values.
  • the Van Oss model has been defined for a smooth and homogeneous surface.
  • the silicone surface obtained shows a low surface free energy ( ⁇ ) when compared to ex vivo skin: 19.7 ⁇ 5.0 mJ/m 2 for silicone against 31.5 ⁇ 3.6 mJ/m 2 for ex vivo skin.
  • the addition of the sebum thin layer on the silicone allows reaching a value of 26.7 ⁇ 2.2 mJ/m 2 for the LW component on the NBSM prepared with protocol 2, in good agreement with the value of 28.4 ⁇ 2.8 mJ/m 2 calculated on human living skin explants. Noteworthy those results are in accordance with literature data calculated from in vivo measurements [1].
  • Protocol 1 is less efficient than Protocol 2 to reach properties close to ex vivo human skin. Indeed, one can observe that surfaces prepared using protocol 1 show higher values for the acidic component (3.1 ⁇ 2.0 mJ/m 2 ), in comparison with ex vivo skin (0.5 ⁇ 0.5 mJ/m 2 ). Then, the LW component determined for protocol 1 (19.8 ⁇ 3.1) is lower than the one obtained ex vivo. Protocol 2 is so more appropriate to mimic skin physico-chemistry. In addition, the absence of solvent in Protocol 2 is undoubtedly advantageous for environmental concerns and it also prevents the risk of dissolution of the polymeric material once covered by the sebum. Moreover, optical microscopy proves that sebum distribution was more homogeneous and that lipids crystallization was limited with Protocol 2. For all these reasons, the second protocol was selected and applied for the rest of the study.
  • the NBSM protocol 2 developed in the present invention shows a chemical composition and topographic properties close to ex vivo skin. Moreover, as shown in previous paragraph, the sebum coating has been optimized to be as close as possible to skin physico-chemistry. All these results demonstrate that the NBSM is a relevant skin model to mimic a large range of skin surface properties. In order to show the interest of NBSM, complementary measurements have been performed to evaluate its interactions with cosmetic ingredients and its physico-chemical behaviour after cosmetic products application.
  • Table 7 Description of emulsion used Name Code Application Nivea Creme NC Moisturizing and nourishing W/O emulsion Gel hydroetherique Assanis Family GHA Disinfection aqueous gel Standard Emulsion SE O/W emulsion
  • Contact angle measurements are part of instrumental methods which are used to study spreading properties of emollients on skin.
  • Spreading of emollients is an important purpose for sensory quality of a cosmetic product but also for its efficacy, above all for sunscreens.
  • sun protection factor is on the one hand due to solar filters present in emulsions and on the other hand due to the homogeneity of the residual film once the product spread onto the skin surface.
  • the spreading appears of primary importance [21,22].
  • contact angle measurements were performed with 4 ingredients: CPS, PDC, AO and IHD on the different surfaces studied herein.
  • the hydration state of the VS may be responsible for this result as the presence of water classically tends to increase surface free energy value.
  • the NBSM protocol 2 interestingly appears as a relevant tool to study residual film present on the skin surface after topical application. The physico-chemical characterization of cosmetic residual films is presented below.
  • Characterization of the residual film of an ingredient or an emulsion on skin is a very interesting topic as its homogeneity, composition and stability greatly impact skin surface properties and, consequently, the efficacy of cosmetic actives and products.
  • water contact angle have been measured on VS, NBSM protocol 2 and in vivo at two distinct times (1 and 3 minutes) once a series of cosmetic products applied following the protocol described above. Results are presented on Figure 11 .
  • Water contact angles measured 1 min after surface treatment with cosmetic ingredients are classified as follow: ⁇ water /PDC ⁇ ⁇ water /AO ⁇ ⁇ water /IHD ⁇ ⁇ water /CPS for both in vivo skin and NBSM protocol 2, whereas ⁇ water /IHD ⁇ ⁇ water /PDC ⁇ ⁇ water /AO ⁇ water /CPS for VS.
  • ⁇ water in vivo 93,2 ⁇ 7.8°
  • ⁇ water NBSM 114,2 ⁇ 5.8°
  • ⁇ water vs 104.2 ⁇ 11.8°.
  • ingredients reduce water contact angle values for each surface.
  • results obtained are in accordance with surface tension values (Table 6) of each ingredient: the lower the ingredient surface tension the higher the water contact angle.
  • the ingredient residual film modifies skin composition and surface tension.
  • CPS with low surface tension decreases skin surface energy.
  • NC exhibits the highest values of water contact angle, followed by the hydro alcoholic gel, while SE obtained the lowest values ( Fig 11 ).
  • SE and GHA contain more than 70% of water and isopropyl alcohol respectively which makes the skin more hydrophilic after application whereas for the inverse emulsion NC, its continuous oily phase is more important and makes the skin more hydrophobic.
  • the skin model VS displays surprisingly a water contact angle null for SE. Differences observed for VS in the measurements after emulsion application can be due to its absorption capacity and to its high hydration, as explained previously. Water from deposit drop can interact with the high amount of water contained in VS which decreased contact angle values.
  • Water contact angle measured 3 min after treatment can be useful to evaluate the evolution of residual film on skin at longer time.
  • the GHA shows an important increase in water contact angle between 1 min and 3 min after application. This is probably the result of isopropyl alcohol evaporation. In this case, only non-volatile and non-penetrating ingredients of the product remain on the skin 3 min after application. In opposition, the SE residual film did not significantly evolve after 3 min which means that both penetration and evaporation of compounds are not achieved.
  • the final example of application concerns the use of NBSM to characterize residual film after product application in terms of chemical composition, as shown on infrared spectra on Figure 12 before and after NC application to skin.
  • NBSM to characterize residual film after product application in terms of chemical composition
  • the vibration at 1639 cm -1 is characteristic of the presence of the NC emulsion on the surface.
  • Such an illustration highlights how it can be very interesting to study the chemical composition of the residual film after application and its evolution over time with using NBSM surface.
  • Another perspective covers the investigation of the homogeneity of a residual film by means of IR microscopy or Raman microscopy for instance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Algebra (AREA)
  • Mathematical Analysis (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Computational Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Cosmetics (AREA)
  • Instructional Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP19758994.8A 2018-08-30 2019-08-30 Non-biological skin model Active EP3844737B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306149 2018-08-30
PCT/EP2019/073194 WO2020043873A1 (en) 2018-08-30 2019-08-30 Non-biological skin model

Publications (2)

Publication Number Publication Date
EP3844737A1 EP3844737A1 (en) 2021-07-07
EP3844737B1 true EP3844737B1 (en) 2022-07-27

Family

ID=63667842

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19758994.8A Active EP3844737B1 (en) 2018-08-30 2019-08-30 Non-biological skin model

Country Status (8)

Country Link
US (1) US20210209967A1 (es)
EP (1) EP3844737B1 (es)
JP (1) JP7436055B2 (es)
CN (1) CN113574584B (es)
AU (1) AU2019332978A1 (es)
CA (1) CA3110540A1 (es)
ES (1) ES2927144T3 (es)
WO (1) WO2020043873A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113533649A (zh) * 2021-07-14 2021-10-22 南开大学 一种适用于人体皮肤污染物暴露评估的模拟方法
CN113740491A (zh) * 2021-08-27 2021-12-03 无限极（中国）有限公司 一种用于感官评价的仿真皮肤及其制备方法
WO2024184033A1 (en) * 2023-03-08 2024-09-12 Unilever Ip Holdings B.V. Method for demonstrating the mode of action of a skin care product or component thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481001A (en) * 1983-05-26 1984-11-06 Collagen Corporation Human skin model for intradermal injection demonstration or training
US4877454A (en) * 1988-02-04 1989-10-31 The Kendall Company Model human skin
US5015431A (en) * 1988-02-04 1991-05-14 The Kendall Company Process for making model skin
JP3589558B2 (ja) * 1997-12-15 2004-11-17 株式会社資生堂 人工角層
JP3829001B2 (ja) * 1997-12-15 2006-10-04 株式会社資生堂 人工皮膚
JP2001174392A (ja) * 1999-12-17 2001-06-29 Shiseido Co Ltd 皮脂移行性の評価法
US7037112B2 (en) * 2002-12-20 2006-05-02 Kimberly-Clark Worldwide, Inc. Virtual arm for measurement of humidity, temperature, and water vapor transmission rate in materials
JP5087543B2 (ja) * 2005-08-12 2012-12-05 ザ プロクター アンド ギャンブル カンパニー ケラチン組織の特性を備えるコーティングされた基材
US7549866B2 (en) * 2005-12-15 2009-06-23 Kimberly-Clark Worldwide, Inc. Mannequin with more skin-like properties
US8417474B2 (en) * 2006-02-10 2013-04-09 The Procter & Gamble Company Methods of use of substrate having properties of keratinous tissue
US10144204B2 (en) * 2007-01-08 2018-12-04 The Procter & Gamble Company Substrate having properties of mammalian skin
JP2009062309A (ja) * 2007-09-06 2009-03-26 Mandom Corp 皮膚洗浄用化粧料
JP2011022522A (ja) * 2009-07-20 2011-02-03 Hitoo Okano 皮膚モデル
JP5608282B2 (ja) * 2010-04-05 2014-10-15 イー・エム・デイー・ミリポア・コーポレイシヨン ヒト皮膚様透過性を有するポリマー膜およびこの使用
GB2527513B (en) * 2014-06-23 2021-01-20 Secr Defence Synthetic skin
CN105300848B (zh) * 2015-11-23 2019-02-26 南京中医药大学 一种脂质体人工皮肤膜及其制备方法和在外用制剂中的应用
US10755600B2 (en) * 2016-08-30 2020-08-25 St. Jude Medical, Cardiology Division, Inc. Synthetic tissue phantom for medical evaluation
US11105795B2 (en) * 2018-01-22 2021-08-31 ClearIt, LLC Methods and compositions for simulation of the dermal compartment

Also Published As

Publication number Publication date
CA3110540A1 (en) 2020-03-05
WO2020043873A1 (en) 2020-03-05
US20210209967A1 (en) 2021-07-08
JP7436055B2 (ja) 2024-02-21
EP3844737A1 (en) 2021-07-07
AU2019332978A1 (en) 2021-03-11
ES2927144T3 (es) 2022-11-02
CN113574584A (zh) 2021-10-29
JP2021535448A (ja) 2021-12-16
CN113574584B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
EP3844737B1 (en) Non-biological skin model
Bhushan Nanotribological and nanomechanical properties of skin with and without cream treatment using atomic force microscopy and nanoindentation
JP5970184B2 (ja) 化粧料の評価方法
Čuříková et al. Simplified stratum corneum model membranes for studying the effects of permeation enhancers
KR101455684B1 (ko) 피부 장벽 개선 및 피부 재생 효과를 갖는 액정유화 화장료 조성물
KR102107865B1 (ko) 주름 개선 효과에 관해 화장료를 평가하는 방법
JP2022506749A (ja) 架橋される材料
Kim et al. Combined skin moisturization of liposomal serine incorporated in hydrogels prepared with carbopol ETD 2020, rhesperse RM 100 and hyaluronic acid
Bhushan Biophysics of skin and its treatments
Merle et al. Physical and chemical perturbations of the supramolecular organization of the stratum corneum lipids: in vitro to ex vivo study
Rossi et al. Determination of the Surface Free Energy of Skin and the Factors Affecting it by the Contact Angle Method
Perez et al. Physicochemical stability and rheologic properties of a natural hydrating and exfoliating formulation beneficial for the treatment of skin xeroses
Finch Chemical modification of skin mimic systems
LIFENG Skin permeation enhancement by terpenes for transdermal drug delivery
Liu Biomechanics of the human skin barrier
Zamani Gerashi Factors affecting the microstructure and permeability of lipid model membranes
Strati Stratum corneum models as pharmaceutical formulations and diastereomeric CER (AP) investigated in 2D and 3D model systems
EP4210837A1 (fr) Nouvelle émulsion mimant la peau
CN117898956A (zh) 一种丰唇唇霜组合物
Berkey Measuring, Mitigating, and Modeling the Impact of Skin Treatments and Solar Exposure on the Barrier Function of Human Stratum Corneum
Potter et al. Chaper 16-Stratum Corneum Biomechanics
JOSEPH Physical characterization of vernix caseosa: Implications for biological function
Ahmed Characterization and evaluation of the barrier properties of different skin models as an alternative model for human skin
Viegas Characterisation of a Novel Flexing Diffusion Cell (CutaFlex TM) for Assessing Dermal Exposure to Nanoparticles
IT201900014607A1 (it) Nanofibroina e composizioni che la contengono per applicazioni in cosmetica

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220317

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019017559

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1507601

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2927144

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221102

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221128

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221027

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1507601

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221127

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221028

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220830

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019017559

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

26N No opposition filed

Effective date: 20230502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230825

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231027

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240821

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240821

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240826

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240821

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240830

Year of fee payment: 6